Efavirenz 400 mg daily remains non-inferior to 600 mg: 96 week data from the double-blind placebo-controlled ENCORE1 study

摘要

IntroductionENCORE1 compared the efficacy and safety of reduced versus standard dose efavirenz (EFV) with tenofovir/emtricitabine (TDF/FTC) as first-line HIV therapy. The primary analysis at 48 weeks showed 400 mg EFV was safe and virologically non-inferior to 600 mg. This analysis explores over 96 weeks the durability of efficacy and safety.